Document is current
Any future updates will be listed below
-
Authors
Andersen, Mads Hald https://orcid.org/0000-0002-2914-9605
-
Funding
Funding for this research was provided by:
Herlev Hospital (N/A)
- License Information
-
More Information
Article History
Received: 21 October 2025
Revised: 18 February 2026
Accepted: 20 March 2026
First Online: 10 April 2026
Competing interests
: M.H.A. is named an inventor on various patent applications relating to the therapeutic use of TMAs for vaccination. The rights of the patent applications have been transferred to Copenhagen University Hospital, Herlev, according to the Danish Law of Public Inventions at Public Research Institutions. The capital region has transferred these patents to the company IO Biotech, whose purpose is to develop immune-modulatory vaccines for cancer treatment.
